Aptevo Therapeutics Inc Expected to Post Q1 2021 Earnings of ($0.16) Per Share (NASDAQ:APVO)

Aptevo Therapeutics Inc (NASDAQ:APVO) – Analysts at Piper Jaffray Companies issued their Q1 2021 earnings estimates for shares of Aptevo Therapeutics in a research report issued to clients and investors on Thursday, November 7th. Piper Jaffray Companies analyst E. Tenthoff anticipates that the biotechnology company will earn ($0.16) per share for the quarter. Piper Jaffray Companies also issued estimates for Aptevo Therapeutics’ Q2 2021 earnings at ($0.15) EPS, Q3 2021 earnings at ($0.16) EPS and FY2021 earnings at ($0.67) EPS.

Several other research analysts have also recently weighed in on the company. Zacks Investment Research cut Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 16th. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

APVO stock traded up $0.02 during midday trading on Monday, hitting $0.67. The company’s stock had a trading volume of 7,721 shares, compared to its average volume of 519,858. The stock’s 50-day moving average price is $0.61 and its 200 day moving average price is $0.75. The company has a quick ratio of 2.21, a current ratio of 2.63 and a debt-to-equity ratio of 0.89. Aptevo Therapeutics has a 1 year low of $0.49 and a 1 year high of $3.65. The stock has a market cap of $29.33 million, a price-to-earnings ratio of -0.28 and a beta of 2.44.

Aptevo Therapeutics (NASDAQ:APVO) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.01. Aptevo Therapeutics had a negative return on equity of 148.97% and a negative net margin of 195.98%. The business had revenue of $9.01 million during the quarter, compared to the consensus estimate of $8.05 million.

A number of hedge funds have recently bought and sold shares of the business. Stonepine Capital Management LLC boosted its position in Aptevo Therapeutics by 0.7% in the second quarter. Stonepine Capital Management LLC now owns 3,922,891 shares of the biotechnology company’s stock worth $3,478,000 after purchasing an additional 28,672 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Aptevo Therapeutics by 6.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,350,000 shares of the biotechnology company’s stock valued at $2,083,000 after buying an additional 150,000 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Aptevo Therapeutics by 32.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,644,856 shares of the biotechnology company’s stock valued at $1,458,000 after buying an additional 406,930 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Aptevo Therapeutics by 312.8% during the 2nd quarter. Acadian Asset Management LLC now owns 632,507 shares of the biotechnology company’s stock valued at $560,000 after buying an additional 479,278 shares during the last quarter. Finally, Worth Venture Partners LLC lifted its position in shares of Aptevo Therapeutics by 4.4% during the 2nd quarter. Worth Venture Partners LLC now owns 447,669 shares of the biotechnology company’s stock valued at $397,000 after buying an additional 18,669 shares during the last quarter. 32.90% of the stock is currently owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations.

Featured Article: What is Cost of Capital?

Earnings History and Estimates for Aptevo Therapeutics (NASDAQ:APVO)

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.